** Shares of drug developer Dogwood Therapeutics DWTX.O rise ~13% to $12.59
** Co's largest shareholder, CK Life Sciences, is converting a $19.5 mln loan into preferred equity stock
** DWTX says it is issuing 284.2638 shares of preferred stock to CK Life Sciences, which owns 15.9% of co's outstanding shares - LSEG
** Co says it can now focus on its mid-stage clinical trial for its pain treatment drug, Halneuron, which targets chemotherapy-induced neuropathic pain
** DWTX fell ~83% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))